CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income (loss)	$ 2,620,000	$ (1,000)
Adjustments to reconcile net income (loss) to net cash:
Stock compensation expense	227,000	262,000
Foreign exchange loss (gain)	47,000	61,000
Depreciation and amortization	624,000	652,000
Deferred income taxes	(2,655,000)	19,000
Provision for inventory reserves	23,000	12,000
Other	231,000	84,000
Other changes in assets and liabilities:
Accounts receivable, net	152,000	(1,551,000)
Inventories	(332,000)	(1,063,000)
Costs in excess of billings and unbilled receivables	328,000	81,000
Prepaid expenses and other assets	263,000	(150,000)
Accounts payable	(410,000)	796,000
Accrued expenses and other liabilities	(542,000)	204,000
Deferred revenue	(140,000)	127,000
Net cash from operating activities	436,000	(467,000)
Cash flows from investing activities:
Purchases of property, plant and equipment	(228,000)	(931,000)
Purchase of intangibles	(64,000)	(51,000)
Net cash from investing activities	(292,000)	(982,000)
Cash flows from financing activities:
Proceeds from issuance of common stock	8,000	7,000
Net proceeds from issuance of convertible notes	0	390,000
Principal payments on capital leases	(55,000)	(69,000)
Proceeds from (payments of) line of credit, net	0	735,000
Proceeds from (payments of) bank and subordinated debt, net	(354,000)	(76,000)
Net cash from financing activities	(401,000)	987,000
Effect of exchange rates on cash and cash equivalents	(51,000)	(19,000)
Net change in cash and cash equivalents	(308,000)	(481,000)
Cash and cash equivalents, beginning	2,607,000	1,295,000
Cash and cash equivalents, ending	2,299,000	814,000
Non cash activities:
Assets purchased under capital leases	0	134,000
Recapitalization of Xcede - conversion of non controlling notes payable to preferred stock	(3,103,000)	0
Subsidiary stock options issued to settle liabilities	75,000	0
Subsidiary debt issued to fund research activities	$ 500,000	$ 0